ACAD vs COO
ACADIA Pharmaceuticals Inc. vs Cooper Companies (The) — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
67
Buy
VS
COO
Cooper Companies (The)
68
Buy
| Metric | ACAD | COO |
|---|
| AI Score |
67
|
68
|
| Price |
$30.59
|
$73.45
|
| P/E Ratio |
13.18×
|
64.24×
|
| ROE |
31.9%
|
4.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
64.4%
|
| Debt / Equity |
0.06×
|
0.30×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
61.2
|
54.1
|
| Beta |
0.845
|
0.823
|
| Expected Upside |
—
|
+0.1%
|
AI Committee View
Current Innellis committee reasoning for ACAD versus COO.
COO leads by 1 points.
COO scores 68/100 (Buy) versus ACAD at 67/100 (Buy).
ACAD Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- P/E of 12.9 is inexpensive for the broad market — Value
- ROE of 32.4% shows genuine earnings power backing the valuation — Value
- Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
- Bollinger bandwidth of 22.8% signals elevated volatility — Risk
COO Committee View
80% agreement
5 analysts
The primary driver is 4 consecutive earnings beats -- consistent execution. The main limiting factor is macd histogram negative -- bearish momentum. The committee is constructive but not yet at full conviction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical